EXL named a Leader and a Star Performer in Everest Group's 2025 Life and Annuities Insurance BPS and TPA PEAK Matrix® Assessment
NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ: EXLS), a global data and AI company, announced it has been named a Leader and a Star Performer in Everest Group's Life and Annuities (L&A) Insurance Business Process Services (BPS) and Third-Party Administrator (TPA) PEAK Matrix® Assessment 2025.
This is the second consecutive year that EXL has earned this distinction. Everest Group cites EXL's digital integration of analytics and AI solutions, robust engagement models, and in-house domain expertise as key to its market success.
'EXL has demonstrated growth in the L&A Insurance BPS and TPA market, driven by its digital transformation-led strategy and flexible engagement models, including BPaaS and TPA constructs. This approach has reinforced EXL as a partner of choice for enterprises,' said Sahil Chaudhary, practice director, Everest Group. 'EXL continues to invest in upskilling and talent development through in-house microlearning programs on emerging technologies and industry certifications. Collectively, these efforts have positioned it as a Leader and Star Performer in the Everest Group L&A Insurance BPS and TPA PEAK Matrix® Assessment 2025.'
Each year, Everest Group presents detailed assessments of L&A insurance BPS and TPA providers. This year's assessment includes 24 companies. Firms are evaluated based on their vision, capabilities, and market impact. Researchers determine an organization's positioning based on Everest Group's annual RFI process, interactions with leading L&A insurance BPS and TPA providers, client reference checks, and ongoing analysis of the industry market.
'As the L&A insurance industry undergoes yet another transformation, insurers are grappling with ways to break away from legacy systems and improve operational efficiency," said Vivek Jetley, president and head of insurance and healthcare and life sciences, EXL. "At EXL, we are proud to be accelerating the adoption of intelligent automation into our clients' existing service offerings, including actuarial services, claims management, underwriting, and policy administration, to create more efficient, value-driven decisioning.'
To read more about Everest Group's L&A Insurance BPS and TPA PEAK Matrix® Assessment 2025, click here. For more information about EXL's solutions for the insurance industry, click here.
Disclaimer
Licensed extracts taken from Everest Group's PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.
About EXL
EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 59,000 employees spanning six continents. For more information, visit www.exlservice.com.
About Everest Group Everest Group is a leading global research firm helping business leaders make confident decisions. Everest Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at www.everestgrp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as 'may,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate' or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.
ContactsMedia Keith Little+1 703-598-0980 media.relations@exlservice.com
Investor RelationsJohn Kristoff+1 212 209 4613IR@exlservice.comSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation
A record number of exhibitors and unprecedented investor participation defined this year's success. New business matchmaking milestones further elevated BEYOND Expo 2025. Fund at First Pitch, Innovation Awards, Founder Stage and Founders Club Among Key Initiatives Supporting Entrepreneurs from across Asia. MACAO, June 9, 2025 /PRNewswire/ -- The 5th BEYOND Expo concluded at The Venetian® Macao's Cotai with unprecedented momentum, cementing its role as a cornerstone for Asian tech innovation under the theme "Empowering Asia, Bridging the World." From inspiration by startups to wisdom shared by Alibaba Group's Chairman Joe Tsai, tech leaders and visionaries illustrated BEYOND Expo's commitment to supporting tech innovation in Asia. This year's BEYOND Expo attracted a record-breaking 25,000+ visitors, 800+ exhibitors, 300 media representatives, and over 800 investors, including more than 300 family offices and LPs, from over 120 countries — the highest numbers to date. Covering sectors from AI, Healthcare, Mobility, Property Tech, Clean Energy, Robotics, Fashion Tech, Sports Tech, to Web3, this year marked the largest and most content-rich BEYOND Expo to date. Beyond the breadth of industry focus, BEYOND Expo also deepened its commitment to regional collaboration through a series of forums spotlighting strategic markets such as Southeast Asia, Japan, the Middle East, Latin America, and Europe. This dual emphasis on sector innovation and regional opportunity positioned BEYOND Expo as one of the most prominent and impactful pan-Asian tech gatherings ever held. BEYOND Expo Co-Founder Dr. LU Gang said, "This year there has been a tremendous energy around BEYOND Expo, fueled by Asia's rapid rise in frontier technologies and a greater desire for inter-Asian collaboration and cooperation. The products and solutions on display demonstrate just how much AI is transforming so many aspects of our lives, from the food we eat and the clothes we wear to how we interact with each other. Our ecosystem partners, including media, investors, incubators, and suppliers, are driving this momentum and nurturing next-generation technologies." BEYOND Expo recognized some of these innovators by presenting 25 Innovation Awards and hosting competitions such as Fund at First Pitch (FAFP), which attracted 150 competitors. JumpStart Media Executive Chairman James Kwan chaired the 2025 FAFP finale, which featured three high profile investors as judges: Artest Management Group (AMG) Chairman, Metta World Peace; Gobi Partners Co-founder and Chairperson, Thomas Tsao, and Lingotto Innovation Managing Partner & Co-Head, Morgan Samet. BEYOND Expo Co-Founder Jason Ho added, "The impact of BEYOND Expo 2025 extends beyond the event itself. It has matured into a year-round ecosystem with the BEYOND Global Network and BEYOND Founders Club, initiatives that support the global expansion of Asian tech companies and foster knowledge and resource sharing among entrepreneurs, driving technological advancements to address global challenges." Most International Speaker Lineup and Dynamic Stage Experience in BEYOND's History During the three-day exhibition, BEYOND Expo delivered its most internationally diverse and intellectually stimulating content lineup ever. More than 300 speakers from across the globe, including Greater China, the United States, United Kingdom, Portugal, the Netherlands, Belgium, Brazil, Mexico, UAE, Singapore, Japan, South Korea, Thailand, Malaysia, Indonesia, Vietnam, Pakistan, and beyond, took the stage to share bold ideas and transformative insights. Seven thematic stages were strategically placed across the expo floor, offering an immersive and accessible experience for all attendees. From visionary keynotes to dynamic roundtables, these sessions spanned global trends and regional collaboration, across topics such as: Global Vision Summits: The BGlobal Summit, Global Investment Summit, Wealth Summit and Cross-Border E-commerce Ecosystem Forum explored how Asian innovators are scaling globally. Regional Collaboration Forums: Asia-Europe Tech Forum, Asia-Latam Tech Forum, ORIGIN Southeast Asia Conference, Japan Tech Forum, and the Zayed Sustainability Prize China Forum created rare opportunities for cross-regional partnerships and investment dialogues. Frontier Tech Spotlights: AI Summit, Web3 + AI Forum, Founders Talk, Transportation & Mobility Summit, Sports Tech Forum, Fashion Tech Forum, International Industrial Design Forum, and Gen Z Founder Forum brought cutting-edge conversations and industry innovation to the forefront. Women in Tech: The SheTech Summit championed greater representation and leadership for women in the tech ecosystem. This comprehensive summit program reinforced BEYOND Expo's status as a leading platform for driving innovation, collaboration, and growth in Asia's technology ecosystem. A Special Focus on Asia's Unicorn Founders The Opening Ceremony on May 21 convened some of the most influential minds in Asian tech to explore the theme "What's Next?". Among the featured speakers were Dr. Jian Wang, President of Zhejiang Lab and Founder of Alibaba Cloud; Carl Pei, Co-founder and CEO of Nothing; Dr. Burt Guo, CEO and Chief Scientist of Sichuan Aerofugia; Yuekai Zhao, Co-founder of Agile Robots SE; and Jingkang Liu, Founder of Insta360. A standout moment was the roundtable with unicorn founders, where these leaders exchanged bold ideas on scaling globally from Asia, a region rapidly emerging as the heartbeat of next-gen innovation. Building on that momentum, the two-day Founder Talk featured over 30 trailblazing founders driving breakthroughs in AI, robotics, consumer tech, and sustainability. The stage also welcomed over 25 rising stars at the Gen Z Founder Forum and Gen Z Awards Ceremony, where young innovators showcased tech-driven solutions to global challenges. From unicorn visionaries to next-generation disruptors, BEYOND Expo celebrated the full spectrum of entrepreneurial ambition shaping the future of Asia and beyond. Media Day Previewed BEYOND Expo 2025's Innovation Held ahead of the main exhibition, the Media Day welcomed Beyond Expo product showcases, Media Day facilitated meaningful exchanges between innovators and the global press, setting the stage for a high-impact expo with worldwide reach. A showcase for the tech-inspired products of the future BEYOND Expo showcased over 1,000 high-tech products, targeting daily lifestyle and sustainability solutions. These included biodegradable materials, enhanced earphones and speakers, smart eyewear, healthy food, humanoids, medical devices, robotic pets, sleeping aids, and future mobility solutions. B2B applications included AI-reality-inspired software, medical devices, energy-saving and industrial robots. Unmatched B2B Engagement and Industry Matchmaking For the first time, BEYOND Expo hosted multiple on-site business matchmaking sessions over three days, connecting key industry players. Major corporations such as China State Construction International, China Taiping, Sands China, CATL, Tokyu Land Corporation, BMW Group, Sony, Makuake, Mitsubishi Estate, and Panasonic participated, signaling strong demand for real-time, high-value engagement between corporates and innovators. These sessions provided both sides with an efficient platform to identify strategic partners and explore collaborative opportunities. International Delegations and Buyer Groups Expand Global Reach This year also saw the participation of numerous international delegations and "buyer groups," further amplifying BEYOND Expo's reach. Representatives from Deloitte China, BMW Group, Japanese buyer groups, Western crowdfunding platform executives, and prominent overseas influencers all engaged with exhibitors, many of whom reported valuable feedback and new partnership leads. BEYOND Expo was positioned as a global gateway for companies aiming to scale across Asia and beyond, while spotlighting the region's confidence and capacity in innovation. Backing the Region's Boldest Innovators BEYOND Expo further strengthened its commitment to supporting emerging companies with expanded programming tailored for startups. At the heart of Growth Park, a newly launched multi-purpose stage served as a high-impact arena for product unveilings, startup-focused events, and strategic partnership announcements. The Demo Stage, a headline feature of this space, gave rising tech companies the chance to debut their latest innovations in front of a global audience, including investors, media, and industry leaders. After Hours: Where Innovation Met Entertainment As day turned to night, BEYOND Expo 2025 transformed into a vibrant celebration where technology and culture seamlessly converged. Each evening featured exclusive events that blended immersive entertainment with meaningful networking opportunities. From Welcome Night and Gala Dinner to dynamic pool parties energized by live DJs, an electrifying performance by Jax Jones, and the breathtaking Cirque Le Soir circus spectacle, BEYOND Expo offered unforgettable experiences that extended the spirit of innovation well beyond the conference halls. BEYOND Expo 2025 Partners BEYOND Expo 2025 was made possible with the generous support of Strategic Partners China State Construction International Holdings Limited and China Taiping; Platinum Partners Taobao 88VIP and Macau Pass | MPay; Gold Partner Nam Kwong (Group) Company Limited; Sustainability Partner the Zayed Sustainability Prize; and Venue Partner Sands China Ltd. Additional partners included Asian Family Legacy Foundation, ChainNeXT, Design School of Hunan University, Founders Breakfast, Greenwich Economic Forum, GWA, MAP, INNOBAKER, IESt, Lushan Laboratory, ReGACY Innovation Group, RMI, Sherewires, SIEF, TNGlobal, wteam, and yehyehyeh. A full list of participating companies can be found here: BEYOND EXPO 2025 About BEYOND Expo The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia's leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions. BEYOND Expo has attracted participation from Asia's Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. View original content to download multimedia: SOURCE Beyond EXPO


Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit